Gilles Dadaglio

Multiple Myeloma (MM) is an incurable malignancy characterized by the uncontrolled expansion of plasma cells in the bone marrow. While proteasome inhibitors like bortezomib efficiently halt MM progression drug resistance inevitably develop, and novel […]

The malignant transformation of cells translates into a major worldwide health, social and economic burden. Efforts to define the etiology of cancer, along with the development of new therapeutic approaches to treat them, would […]

We are member of the ADITEC Consortium, a collaborative research programme that aims to accelerate the development of novel and powerful immunisation technologies for the next generation of human vaccines. Scientists from 13 countries […]

CyaA-based therapeutic cancer vaccines Based on our discovery that a bacterial protein, the adenylate cyclase (CyaA), binds to dendritic cells (DCs), we have developed a highly efficient vector capable of targeting a wide range […]

Mycobacterium ulcerans causes Buruli ulcer, a neglected tropical skin disease manifesting as chronic wounds that can leave victims with major, life-long deformity and disability. Differently from other mycobacteria, including the related M. tuberculosis and […]

Human Papillomaviruses (HPV) are the major cause of human cervical cancer. We have developed a therapeutic tumor vaccine, the CyaA-E7 vaccine, that can induce specific responses against the HPV E7 oncoprotein and eliminate E7 […]